<DOC>
	<DOCNO>NCT00883753</DOCNO>
	<brief_summary>This study extension study MA21573 [ NCT00750880 ] , open label single arm study investigate safety , tolerability efficacy tocilizumab monotherapy , combination therapy non-biological disease-modifying antirheumatic drug ( DMARDS ) , patient moderate severe active rheumatoid arthritis . Patients complete 24 week core study , least moderate European League Against Rheumatism ( EULAR ) response , eligible enter long-term extension study , receive tocilizumab 8 mg/kg intravenous ( iv ) every 4 week . The anticipated time study treatment 1-2 year , target sample size &gt; 500 individual .</brief_summary>
	<brief_title>An Extension Study MA21573 , Evaluating Tocilizumab Patients With Active Rheumatoid Arthritis Inadequate Response Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor ( TNF ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>patient complete 24week MA21573 core study , least moderate response base EULAR definition criterion adverse event ( AEs ) , serious adverse event ( SAEs ) condition lead unacceptable risk continue treatment . MA21573 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>